$AVTX News

Guggenheim Maintains Buy on Avalo Therapeutics, Lowers Price Target to $48

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $30

Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate

Avalo Therapeutics Files Prospectus For Offering Up To 128,189 Common Shares On Behalf Of Selling Shareholders

Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

Avalo Therapeutics To Be Added To Small-Cap Russell 2000 Index And Broad-Market Russell 3000 Index, Effective June 26

Avalo Therapeutics Advances AVTX-010, Long-Acting Next-Gen Anti-IL-1β mAB With Potential For Development In HS And Additional Inflammatory Disorders; IND Submission Planned For H1 2027

B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35

Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further

Citizens Maintains Market Outperform on Avalo Therapeutics, Lowers Price Target to $55

These Analysts Revise Their Forecasts On Avalo Therapeutics After Q1 Results

Wedbush Maintains Outperform on Avalo Therapeutics, Lowers Price Target to $34

Mizuho Maintains Outperform on Avalo Therapeutics, Raises Price Target to $45

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Lowers Price Target to $35

Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate

Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60

Avalo Therapeutics: Abdakibart Delivers Breakout Phase 2 HS Data

Avalo Therapeutics Stock Soars After Positive LOTUS Trial Results

Citizens Maintains Market Outperform on Avalo Therapeutics, Raises Price Target to $62

Wedbush Maintains Outperform on Avalo Therapeutics, Raises Price Target to $40